Ceritinib in the treatment of ALK-positive patients with nonsmall-cell lung cancer

by K. K. Laktionov, E. V. Reutova
Published 2019-06-01

Rational approach to the treatment of EGFR-positive lung cancer

by E. V. Reutova, K. K. Laktionov, D. I. Yudin, M. S. Ardzinba
Published 2019-12-01

TARGETED THERAPY OF LUNG CANCER WITH THE ROS1 REARRANGEMENT

by K. K. LAKTIONOV, E. V. REUTOVA, M. S. ARDZINBA, N. A. MESCHERYAKOVA
Published 2017-06-01

Experience of using сrizotinib in patients with ALKpositive non-small cell lung cancer

by E. V. Reutova, L. V. Laktionova, D. T. Marinov, D. A. Peregudov, T. N. Borisova
Published 2020-07-01

Prospects for the development of adjuvant therapy for non-small cell lung cancer

by K. K. Laktionov, A. M. Kazakov, E. V. Reutova, M. S. Ardzinba, A. L. Arzumanian
Published 2020-11-01

Clinical case of use of osimertinib in a patient with disseminated EGFR-mutated non-small cell lung cancer in the first-line therapy

by K. A. Sarantseva, K. K. Laktionov, E. V. Reutova, D. I. Yudin, V. V. Breder
Published 2020-12-01

Firsthand experience of chemoradiotherapy in patients with localized small cell lung cancer. Retrospective assessment

by A. E. Kuzminov, T. N. Borisova, V. V. Breder, E. V. Reutova, T. D. Barbolina, K. K. Laktionov
Published 2020-07-01

Three-year results of application of nivolumab in patients with non-small cell lung cancer in clinical practice of the N.N. Blokhin Russian Cancer Research Center

by K. K. Laktionov, K. A. Sarantseva, D. I. Yudin, V. V. Breder, E. V. Reutova, K. P. Laktionov
Published 2019-12-01

A clinical case of 3-year highly efficient pembrolizamable therapy of metasatic lung adenocarcinoma

by K. K. Laktionov, D. I. Yudin, K. A. Sarantseva, K. P. Laktionov, V. V. Breder, E. V. Reutova
Published 2018-07-01

Pseudoprogression in patients on immunotherapy

by D. I. Yudin, K. K. Laktionov, K. A. Sarantseva, V. V. Breder, E. V. Reutova, O. I. Borisova, M. S. Ardzinba
Published 2019-06-01

Phenotypic transformation as a cause of secondary drug resistance to osimetinib clinical observation

by L. A. Nelyubina, E. V. Reutova, K. K. Laktionov, D. I. Yudin, D. T. Marinov, E. N. Kozak, V. V. Mochalnikova
Published 2018-11-01

A preliminary results of integrated chemotherapy with EGFR receptor tyrosine kinase inhibitors in patients with non-small-cell-lung cancer harboring EGFR mutation

by K. K. Laktionov, D. I. Yudin, V. V. Breder, E. V. Reutova, K. P. Laktionov, D. T. Marinov, D. A. Peregudov, M. S. Ardzinba
Published 2019-06-01

THE FIRST CLINICAL EXPERIENCE WITH AFATINIB IN RUSSIAN FEDERATION

by К. К. LAKTIONOV, М. V. PEREGUDOVA, V. V. BREDER, E. V. REUTOVA, D. A. PEREGUDOV, M. S. ARDZINBA, P. A. CHERNENKO, D. T. MARINOV
Published 2016-12-01

Will neo-adjuvant immunotherapy become a new paradigm in the treatment of lung cancer patients

by K. K. Laktionov, V. V. Breder, D. I. Yudin, K. A. Sarantseva, L. V. Laktionova, M. S. Ardzinba, E. V. Reutova, A. V. Egorova
Published 2019-12-01

Combination of chemoradiation therapy with immunotherapy in the treatment of patients with inoperable stage III non-small cell lung cancer

by N. V. Marinichenko, K. K. Laktionov, A. V. Nazarenko, E. V. Reutova, Merab S. Ardzinba, V. L. Utkina, T. N. Borisova, A. A. Fedorova, Milada S. Ardzinba
Published 2020-12-01

Immuno-related endocrinopathy in patients treated with immune checkpoint inhibitors

by D. I. Yudin, K. K. Laktionov, K. A. Sarantseva, O. I. Borisova, V. V. Breder, E. V. Reutova, M. F. Beloyartseva, S. Yu. Kruteleva, I. A. Dzhanyan
Published 2020-07-01

New possibilities in the treatment of EGFR mutation-positive non-small-cell lung cancer patients after the progression on a 1st and 2nd generation EGFR tyrosine kinase inhibitors

by K K Laktionov, E V Reutova, L A Nelyubina, M Yu Pitkevich, M A Okruzhnova, M S Ardzinba, D I Yudin, I A Demidova, A R Zaretsky
Published 2018-06-01